OKT3-induced cytokine-release syndrome: occurrence beyond the second dose and association with rejection severity.
Vasquez
E M
EM
University of Illinois, Chicago 60612.
Fabrega
A J
AJ
Pollak
R
R
D016207:Cytokines / Q000378:metabolism*; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000276:immunology / Q000473:pathology* / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology; D016853:Muromonab-CD3 / Q000009:adverse effects*; D012189:Retrospective Studies; D013577:Syndrome
D016207:Cytokines; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3